Trastuzumab derived HER2-specific CARs for the treatment of trastuzumab-resistant breast cancer: CAR T cells penetrate and eradicate tumors that are not accessible to antibodies
Open Access
- 11 April 2020
- journal article
- research article
- Published by Elsevier BV in Cancer Letters
- Vol. 484, 1-8
- https://doi.org/10.1016/j.canlet.2020.04.008
Abstract
No abstract availableKeywords
Funding Information
- Hungarian Scientific Research Fund
This publication has 29 references indexed in Scilit:
- Elimination of Progressive Mammary Cancer by Repeated Administrations of Chimeric Antigen Receptor-Modified T CellsMolecular Therapy, 2014
- Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapiesBreast Cancer Research and Treatment, 2012
- Naive, effector and memory CD8 T-cell trafficking: parallels and distinctionsImmunotherapy, 2011
- A Herceptin-Based Chimeric Antigen Receptor with Modified Signaling Domains Leads to Enhanced Survival of Transduced T Lymphocytes and Antitumor ActivityThe Journal of Immunology, 2009
- Immunotherapy for Osteosarcoma: Genetic Modification of T cells Overcomes Low Levels of Tumor Antigen ExpressionMolecular Therapy, 2009
- Natural killer cells remember: An evolutionary bridge between innate and adaptive immunity?European Journal of Immunology, 2009
- Blocking NK Cell Inhibitory Self-Recognition Promotes Antibody-Dependent Cellular Cytotoxicity in a Model of Anti-Lymphoma TherapyThe Journal of Immunology, 2008
- ErbB-directed immunotherapy: Antibodies in current practice and promising new agentsImmunology Letters, 2008
- Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumorCancer Letters, 2008
- Trastuzumab causes antibody-dependent cellular cytotoxicity–mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistanceMolecular Cancer Therapeutics, 2007